Metabolic Peptide Combinations: An Evidence Review
What human trials show for semaglutide and tesamorelin, what remains preclinical for AOD-9604 and 5-Amino-1MQ, and why their combination is untested.
The four compounds often grouped into a “metabolic stack” have very different evidence and regulatory histories. No controlled trial has established that combining semaglutide, AOD-9604, 5-Amino-1MQ, and tesamorelin improves weight loss or safety. A plausible mechanism is a research question, not proof of a useful combination.
Evidence by component
| Compound | What has been studied in people | What the result means |
|---|---|---|
| Semaglutide | Large randomized obesity trials, including STEP 1 | An evidence-based obesity treatment in its approved products and indicated populations. Trial outcomes cannot be assigned to a multi-compound regimen. |
| AOD-9604 | An obesity development program; FDA's Pharmacy Compounding Advisory Committee briefing describes a 536-person study that did not show significant weight loss versus placebo | Proposed fat-loss mechanisms and animal findings have not established clinical weight-loss benefit. |
| 5-Amino-1MQ | The cited NNMT-inhibitor work is preclinical | This is a small molecule, not a peptide. Mouse results cannot supply a human dose, efficacy estimate, or safety profile. |
| Tesamorelin | Trials in adults with HIV-associated lipodystrophy | Its FDA label limits the indication to reducing excess abdominal fat in that population and states it is not indicated for weight-loss management. |
Semaglutide and tirzepatide also cannot be compared by taking the largest percentage from unrelated trials. SURMOUNT-5 is a direct comparison in a defined study population; product selection still depends on indication, contraindications, tolerability, and access.
Why a multi-compound claim is premature
Different proposed pathways do not guarantee additive benefit. AOD-9604 failed to demonstrate meaningful weight loss in the large study summarized by FDA. For 5-Amino-1MQ, human efficacy and adverse effects remain uncharacterized. Tesamorelin can raise IGF-1 and affect glucose tolerance according to its label. There are no human interaction or combined-outcome data for this four-compound regimen. In particular, semaglutide's glucose effects cannot be assumed to cancel another drug's glucose risk.
Descriptions of “synergy,” body recomposition, muscle preservation, or a preferred dosing cycle for this combination are unsupported. The individual product labels and trial protocols are specific to their own formulations and populations; they are not a schedule for stacking compounds.
Questions worth testing
- Does adding another agent to an approved obesity treatment improve outcomes that matter to patients, beyond the approved treatment alone?
- Are any benefits sustained, and what happens to glucose, IGF-1, lean mass, and adverse events?
- Can a proposed combination be manufactured consistently and studied with a clearly defined population and comparator?
For current US product and compounding distinctions, see Peptide Regulatory Status. For newer amylin and incretin trial programs, see Amylin and Incretin Peptides in 2026.
References
Longevity Peptides: Evidence and Regulatory Status
An evidence review of epithalon, MOTS-c, elamipretide, humanin, and 5-Amino-1MQ, including elamipretide's specific Barth syndrome approval.
The Ultimate Nootropic Stack: Semax, Selank, Dihexa, VIP & DSIP
Research guide to the comprehensive cognitive optimization stack combining Semax, Selank, Dihexa, VIP, and DSIP for neurotrophic support, anxiolysis, synaptogenesis, neuroprotection, and sleep architecture optimization.